FDA requires a rare vision loss warning on every GLP-1 drug label
On November 9, 2026 FDA said it is requiring all GLP-1 receptor agonist labels, tirzepatide included, to add a warning about a potential increased risk of NAION, a rare condition that can cause sudden vision loss in one eye.
FDA's Drug Safety Communication says application holders for all GLP-1 receptor agonist medications must add information on non arteritic anterior ischemic optic neuropathy (NAION) to the Warnings and Precautions section of labeling. NAION can cause acute, painless, decreased vision in one eye, including permanent loss.
FDA based the decision on a meta analysis of 126 clinical trials (6.4 cases per 100,000 person years on GLP-1 drugs versus 3.8 on comparators), a Sentinel cohort study and published observational research. It tells professionals to have patients report sudden visual changes immediately, refer suspected cases to an ophthalmologist, and consider stopping the drug unless the benefits clearly outweigh the risk.
- Pharmacies dispensing semaglutide, tirzepatide, liraglutide and other GLP-1 drugs.
- Compounders and telehealth programs supplying GLP-1 products or patient information.
The labeling requirement falls on application holders for approved GLP-1 drugs. Pharmacies are reached through counseling and patient materials, and compounders and telehealth programs through the information they give patients about the same drug class.
| Source published | November 9, 2026 | FDA Drug Safety Communication. |
|---|
GLP-1s are among the highest volume drugs in retail, mail order and telehealth channels. A class wide warning changes what patients should be told at dispensing and what accurate marketing and patient materials look like.
- Add NAION symptoms and the instruction to report sudden vision changes to GLP-1 counseling.
- Update patient handouts, websites and telehealth intake materials that describe GLP-1 risks.
- Route reported vision events through your adverse event reporting process.
No current standard mapping; under review. Patient counseling content is not a named element of the public methodology; under review.
- FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition PrimaryU.S. Food and Drug AdministrationRetrieved Nov 15, 2026
Dated November 9, 2026; labeling requirement; meta analysis figures; advice to health care professionals.
Know where your pharmacy stands before the rules change again.
Certified pharmacies are re-verified nightly against state boards, federal enforcement records and their own websites.